An ongoing dialogue on HIV/AIDS, infectious diseases,
October 26th, 2011
Xigris is Gone — Not That Many ID Docs Will Notice
From the FDA comes this news: FDA notified healthcare professionals and the public that on October 25, 2011, Eli Lilly and Company announced a worldwide voluntary market withdrawal of Xigris [drotrecogin alfa (activated)]. In a recently completed clinical trial (PROWESS-SHOCK trial), Xigris failed to show a survival benefit for patients with severe sepsis and septic shock. Some […]